JP2025513745A5 - - Google Patents
Info
- Publication number
- JP2025513745A5 JP2025513745A5 JP2024557632A JP2024557632A JP2025513745A5 JP 2025513745 A5 JP2025513745 A5 JP 2025513745A5 JP 2024557632 A JP2024557632 A JP 2024557632A JP 2024557632 A JP2024557632 A JP 2024557632A JP 2025513745 A5 JP2025513745 A5 JP 2025513745A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022083269 | 2022-03-28 | ||
| CNPCT/CN2022/083269 | 2022-03-28 | ||
| PCT/CN2023/084213 WO2023185778A1 (en) | 2022-03-28 | 2023-03-28 | Novel anti-fgfr2 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513745A JP2025513745A (ja) | 2025-04-30 |
| JP2025513745A5 true JP2025513745A5 (enExample) | 2026-04-08 |
Family
ID=88199423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557632A Pending JP2025513745A (ja) | 2022-03-28 | 2023-03-28 | 新規抗ｆｇｆｒ２抗体 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4499701A4 (enExample) |
| JP (1) | JP2025513745A (enExample) |
| KR (1) | KR20250042203A (enExample) |
| CN (1) | CN119110806A (enExample) |
| AU (1) | AU2023243773A1 (enExample) |
| CA (1) | CA3246949A1 (enExample) |
| IL (1) | IL315970A (enExample) |
| MX (1) | MX2024011805A (enExample) |
| WO (1) | WO2023185778A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025185559A1 (zh) * | 2024-03-04 | 2025-09-12 | 杭州中美华东制药有限公司 | 抗FGFR2b抗体、其抗体药物偶联物及其用途 |
| CN118772279B (zh) * | 2024-06-28 | 2025-03-25 | 北京普利米特生物科技有限公司 | 抗FGFR2b抗体或其抗原结合片段及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089193A1 (en) * | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| KR102516152B1 (ko) * | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| TWI664977B (zh) * | 2013-10-08 | 2019-07-11 | 第一三共股份有限公司 | 抗ｆｇｆｒ２抗體及其與其他藥劑之組合 |
| JPWO2016171107A1 (ja) * | 2015-04-20 | 2018-03-22 | 第一三共株式会社 | Ｆｇｆｒ２の検出 |
| PE20211213A1 (es) * | 2018-10-05 | 2021-07-05 | Five Prime Therapeutics Inc | Formulaciones de anticuerpos anti-fgfr2 |
| KR20220119471A (ko) * | 2019-12-24 | 2022-08-29 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | 신규한 항fgfr2b 항체 |
| KR20220119144A (ko) * | 2019-12-24 | 2022-08-26 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | 신규한 항fgfr2b 항체 |
| JP7686000B2 (ja) * | 2019-12-24 | 2025-05-30 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | 新規抗ＦＧＦＲ２ｂ抗体 |
-
2023
- 2023-03-28 CN CN202380031311.1A patent/CN119110806A/zh active Pending
- 2023-03-28 AU AU2023243773A patent/AU2023243773A1/en active Pending
- 2023-03-28 KR KR1020247035207A patent/KR20250042203A/ko active Pending
- 2023-03-28 JP JP2024557632A patent/JP2025513745A/ja active Pending
- 2023-03-28 IL IL315970A patent/IL315970A/en unknown
- 2023-03-28 WO PCT/CN2023/084213 patent/WO2023185778A1/en not_active Ceased
- 2023-03-28 EP EP23778143.0A patent/EP4499701A4/en active Pending
- 2023-03-28 CA CA3246949A patent/CA3246949A1/en active Pending
-
2024
- 2024-09-25 MX MX2024011805A patent/MX2024011805A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041845A5 (enExample) | ||
| JP2022506072A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2024504390A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2025513745A5 (enExample) | ||
| JP2023518153A5 (enExample) | ||
| JP2024534265A5 (enExample) | ||
| WO2023060277A1 (en) | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2024535930A5 (enExample) | ||
| JP2023545521A5 (enExample) | ||
| JP2024525916A5 (enExample) | ||
| JP2023517794A5 (enExample) | ||
| JP2023533793A5 (enExample) | ||
| JP2024020436A5 (enExample) | ||
| JP2025508606A5 (enExample) | ||
| JP2025503229A5 (enExample) | ||
| JP2022502079A5 (enExample) |